Castle Biosciences Stock Price, News & Analysis

Castle Biosciences, Inc. (Nasdaq: CSTL) announced a podium presentation on its DecisionDx®-SCC test at the AHNS 10th International Conference from July 22-25, 2021. This 40-gene expression profile test assesses the metastasis risk in high-risk cutaneous squamous cell carcinoma patients. A study involving 278 patients demonstrated significant differences in three-year metastasis-free survival rates based on the DecisionDx-SCC results compared to traditional staging methods. The test enhances risk assessment and informs treatment decisions.

Castle Biosciences (Nasdaq: CSTL) announced data presentations for two gene expression profile tests, DecisionDx-Melanoma and DecisionDx-SCC, at the SDPA Annual Summer Dermatology Conference 2021. DecisionDx-Melanoma predicts melanoma metastasis and recurrence risk, showing that 89% of nurse practitioners view its testing as beneficial to patient care. DecisionDx-SCC assesses metastatic risk in cutaneous squamous cell carcinoma patients, reporting a technical reliability of 96.3% across the first 1000 samples. Both studies underline the clinical utility of these tests in improving treatment decisions.

Castle Biosciences, Inc. (Nasdaq: CSTL) has appointed Kim Caple and Ellen Goldberg to its board of directors, effective immediately. Derek Maetzold, CEO, expressed confidence in their leadership and experience. Caple, currently with Thermo Fisher Scientific, brings expertise in genetic analysis technologies. Goldberg, founder of CHORD Consulting, has a robust background in diagnostics and marketing, notably with the Oncotype DX Breast Cancer Assay. The company specializes in dermatologic diagnostics, providing genomic information for better treatment decisions.

Castle Biosciences, Inc. (Nasdaq: CSTL) has been recognized in the Houston Chronicle’s CHRON 100 list for the second consecutive year, highlighting its success in Market Value, Market Return, and Revenue Growth. The recognition reflects Castle's ongoing growth in genomic diagnostics for dermatologic conditions, primarily through its flagship product, the DecisionDx®-Melanoma. The firm plans to enhance its diagnostic suite further, contributing to its stature as a leader in the sector and aiming to improve patient outcomes.

Castle Biosciences, Inc. (Nasdaq: CSTL) has received approval from the New York State Department of Health for its DecisionDx-SCC test, a gene expression profile test that predicts the risk of cutaneous squamous cell carcinoma metastasis. This approval allows patients in New York access to the test, enhancing informed treatment decisions. The company continues to expand its range of genomic tests, having previously gained approvals for others, and emphasizes its commitment to high standards in laboratory medicine.

AltheaDx has appointed Derek Maetzold to its Board of Directors, enhancing its leadership with expertise in diagnostics and management. Maetzold, CEO of Castle Biosciences (CSTL), has significant experience in growing molecular diagnostics businesses. His addition aims to drive AltheaDx’s growth strategy, especially in the demand for pharmacogenomics testing for mental health, intensified by the pandemic. AltheaDx's flagship product, NeuroIDgenetix, is a Medicare-reimbursed test that enhances clinical decision-making for anxiety and depression treatments.

Castle Biosciences (Nasdaq: CSTL) announces a ribbon-cutting ceremony for its new headquarters in Friendswood, Texas, on May 25, 2021, from 3:00 p.m. to 6:00 p.m. Central time. The expansion reflects the company's commitment to improving patient care in dermatology, particularly for skin cancer. In 2020, the workforce grew by nearly 50%, with further hiring expected in 2021. The new facility will support the company's growth and development of genomic tests, including DecisionDx series for various skin cancers. Castle aims to enhance its offerings in dermatologic diagnostics.

Castle Biosciences (Nasdaq: CSTL) announced a collaboration with the American Skin Association to fund melanoma research. The ASA Castle Biosciences Research Grant was awarded to Dr. Joel Sunshine of Johns Hopkins for his study on 'mRNA Nanoparticle Vaccination for Melanoma Immunotherapy.' CEO Derek Maetzold emphasized the company's commitment to advancing dermatologic disease treatments. ASA has funded over $50 million in melanoma research, underscoring its long-standing dedication to skin disease advancements.